Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Also known as: Systemic Sclerosis Associated Interstitial Lung Disease / Systemic Sclerosis-associated Interstitial Lung Disease / Scleroderma-Associated Interstitial Lung Disease (SSC-ILD) / Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Drug | Drug Name | Drug Description |
---|---|---|
DB09079 | Nintedanib | A triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer. |
DB06273 | Tocilizumab | An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB12775 | Abituzumab | 2 | Terminated | 1 |
DB08879 | Belimumab | 3 | Recruiting | 1 |
DB04951 | Pirfenidone | 3 | Unknown Status | 1 |